Back to Search Start Over

MicroRNA miR-20a-5p targets CYCS to inhibit apoptosis in hepatocellular carcinoma.

Authors :
Olarewaju O
Hu Y
Tsay HC
Yuan Q
Eimterbäumer S
Xie Y
Qin R
Ott M
Sharma AD
Balakrishnan A
Source :
Cell death & disease [Cell Death Dis] 2024 Jun 27; Vol. 15 (6), pp. 456. Date of Electronic Publication: 2024 Jun 27.
Publication Year :
2024

Abstract

Hepatocellular carcinoma is a primary liver cancer, characterised by diverse etiology, late diagnoses, and poor prognosis. Hepatocellular carcinoma is mostly resistant to current treatment options, therefore, identification of more effective druggable therapeutic targets is needed. We found microRNA miR-20a-5p is upregulated during mouse liver tumor progression and in human hepatocellular carcinoma patients. In this study, we elucidated the therapeutic potential of targeting oncogenic miR-20a-5p, in vivo, in a xenograft model and in two transgenic hepatocellular carcinoma mouse models via adeno-associated virus-mediated miR-20a-Tough-Decoy treatment. In vivo knockdown of miR-20a-5p attenuates tumor burden and prolongs survival in the two independent hepatocellular carcinoma mouse models. We identified and validated cytochrome c as a novel target of miR-20a-5p. Cytochrome c plays a key role in initiation of the apoptotic cascade and in the electron transport chain. We show for the first time, that miR-20a modulation affects both these key functions of cytochrome c during HCC development. Our study thus demonstrates the promising 'two birds with one stone' approach of therapeutic in vivo targeting of an oncogenic miRNA, whereby more than one key deregulated cellular process is affected, and unequivocally leads to more effective attenuation of HCC progression and significantly longer overall survival.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2041-4889
Volume :
15
Issue :
6
Database :
MEDLINE
Journal :
Cell death & disease
Publication Type :
Academic Journal
Accession number :
38937450
Full Text :
https://doi.org/10.1038/s41419-024-06841-0